"NCI-H460[H460]人大細胞肺癌細胞全年復蘇|已有STR圖譜

傳代比例：1:2-1:4(首次傳代建議1:2)

生長特性：貼壁生長

【細胞培養(yǎng)經(jīng)驗分享】啟蒙老師的重要性：一般進實驗室都有師兄師姐帶著做，他們就是你做細胞的啟蒙老師。他們的操作手法、細節(jié)、理論講解就成了你操作的準則，如營養(yǎng)液、細胞瓶的擺放位置、滅菌處理程序、開蓋手法、細胞吹打手法等等。要學會他們的正確操作，在第一次的時候就要重視。像養(yǎng)孩子一樣養(yǎng)細胞，細胞有時真的很脆弱，最好每天都去看看它，以防止出現(xiàn)培養(yǎng)箱缺水、缺二氧化碳、停電、溫度不夠等異?，F(xiàn)象，也好及時解決這些意外，避免重復實驗帶來的更大痛苦。好細胞要及時保種：細胞要分批傳代，這樣即使有一批出了問題，還有一批備用的。像后者一般人可能不容易做到。但這是我血的教訓，有一次細胞污染了，全軍覆沒。當時可后悔沒有保種。細胞跟人一樣，不同的細胞，培養(yǎng)特性是不一樣的。培養(yǎng)過程中要細細體會，不同細胞系使用不同的培養(yǎng)基和血清。

換液周期：每周2-3次

LP-1 Cells;背景說明：詳見相關文獻介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關產(chǎn)品有：KYSE520細胞、Colon26細胞、HIBEC細胞

TE-12 Cells;背景說明：詳見相關文獻介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關產(chǎn)品有：SKNBE細胞、U2-OS細胞、SuDHL 1細胞

SW1271 Cells;背景說明：詳見相關文獻介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關產(chǎn)品有：BT325細胞、P3X63 AG8-653細胞、3T3L1細胞

背景信息：該細胞１９８２年由A.F.Gazdar建系，源自一位患有大細胞肺癌的男性的胸腔積。該細胞角蛋白、波形蛋白陽性。

NCI-H460[H460]人大細胞肺癌細胞全年復蘇|已有STR圖譜

產(chǎn)品包裝：復蘇發(fā)貨：T25培養(yǎng)瓶(一瓶)或凍存發(fā)貨：1ml凍存管(兩支)

絕大部分細胞消化只要用胰酶潤洗一遍即可：吸去胰酶后，殘留的那些無法計算體積的附著在細胞表面的微量胰酶在37℃一般不到2min足夠消化細胞(絕大部分1min不到)。對于這些細胞原則上不要用胰酶孵育細胞，連續(xù)這樣傳代，對細胞傷害很大。簡單的程序是PBS潤洗吸去，胰酶潤洗吸去，然后37℃消化。什么算是消化好了呢？不需要把細胞全部消化成間隔分布很離散的單個圓形才算消化好了，一般你肉眼觀察貼壁細胞層，只要能移動了，多半呈沙狀移動，其實已經(jīng)是可以了。一般能移動了，說明細胞與培養(yǎng)基質材料的附著已經(jīng)消失了，細胞之間的附著也已經(jīng)消失了，細胞已經(jīng)獨立分布了(雖然沒有呈現(xiàn)很廣的離散分布)。這個時候應該停止消化，不要等到看到鏡下所有細胞都分離得非常好，間隙很大，才停止。細胞系在貼壁的過程中仍然會聚集，這個是貼壁培養(yǎng)的細胞，尤其是腫瘤細胞的一個特性，你可以嘗試，準備100%的單個細胞懸液，貼壁后觀察細胞，仍然是幾個幾個細胞聚集在一起。一些懸浮培養(yǎng)細胞也是如此，容易聚集，不要過幾個小時就拿出來吹打成單細胞懸液。細胞只要能從基質上脫離下來，即使是成片的(比如Calu-3細胞)，吹打不超過20次(一般10次即可)，成小規(guī)模聚集(10個細胞左右)是正常的，不要再去延長消化時間，等待單細胞懸液出現(xiàn)。比較難消化的細胞：潤洗方法5min還不能消化，以結腸癌細胞為例，比如：HCT15、LS411和KM12細胞，胰酶消化，一般10 cm培養(yǎng)皿，一次加入300ul-500ul就足夠了。即使這樣難消化的細胞，一般不超過5min，即可見細胞成片移動，就應該停止消化。一些正常細胞也會有難消化的時候，比如tsDC細胞，用胰酶孵育，3min左右即可看到成片沙狀移動。

KTCTL-140 Cells;背景說明：腎透明細胞癌；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關產(chǎn)品有：C518細胞、COLO 684細胞、H-1954細胞

3T3F442A Cells;背景說明：脂肪前體細胞；雄性；Swiss albino;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關產(chǎn)品有：Microbiological Associates-104細胞、JB-6 Cl 30細胞、NWA細胞

NCI-H69 Cells;背景說明：詳見相關文獻介紹;傳代方法：１：２—１：４傳代，每周換液２次;生長特性：懸浮生長，聚團;形態(tài)特性：聚團懸浮;相關產(chǎn)品有：H735細胞、PL 45細胞、MHCC 97-H細胞

245A Cells(提供STR鑒定圖譜)

來源說明：細胞主要來源ATCC、ECACC、DSMZ、RIKEN等細胞庫

物種來源：人源、鼠源等其它物種來源

NCI-H460[H460]人大細胞肺癌細胞全年復蘇|已有STR圖譜

形態(tài)特性：上皮細胞樣

細胞培養(yǎng)無菌操作步驟和注意事項：１.打開無菌工作臺及凈化室的紫外燈，消毒半小時以上。２.進入凈化室前先關閉紫外燈，打開超凈臺風機，等待３０min以上，以排盡臭氧。３.穿HAO隔離衣，戴HAO口罩，帽子。４.風淋２分鐘。５.０.１%水泡手，擦干。６.點燃酒精燈;超凈臺內應避免放入過多的物品;使用的吸管，滴管，試管，培養(yǎng)瓶等均事先滅菌。７.打開各類瓶蓋前先過火，以固定灰塵;打開的瓶口、試管口過火焰，鑷子使用前應經(jīng)火焰燒灼。８.水平式風機的超凈臺，應使瓶口斜置，應盡量避免瓶口敞開直立。９.同一根吸管或滴管不應連續(xù)用于幾個不同的細胞系；吸取培養(yǎng)基的吸管應離開培養(yǎng)瓶或試管口０.５cm，避免伸入培養(yǎng)瓶口或試管口；以防止細胞系的互相混雜污染。１０.漏在培養(yǎng)瓶上或臺上的體，立即用酒精棉球擦凈。１１.操作完畢后恢復工作臺面。

HCV-29 Cells;背景說明：膀胱；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關產(chǎn)品有：E.L.4細胞、NCI-H-295細胞、Hmy.2 CIR細胞

CAL27 Cells;背景說明：該細胞１９８２年由J. Gioanni建系，源自一位５６歲白人男性的舌頭中倍的病變部位，角蛋白強陽性;傳代方法：１：６傳代，２—３天換液一次;生長特性：貼壁生長;形態(tài)特性：上皮細胞樣;相關產(chǎn)品有：MDA MB 231細胞、R.K.13細胞、TO175T細胞

V79-4 Cells;背景說明：詳見相關文獻介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關產(chǎn)品有：LAN5細胞、Tissue Culture-1細胞、HPAFII細胞

NBL_S Cells;背景說明：詳見相關文獻介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關產(chǎn)品有：KCL22細胞、HEK.EBNA細胞、Ocular Choroidal Melanoma-1細胞

NPA87-1 Cells;背景說明：詳見相關文獻介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關產(chǎn)品有：SUM 52PE細胞、Y3細胞、HT 1376細胞

NCIH2291 Cells;背景說明：詳見相關文獻介紹;傳代方法：１：３-１：４傳代；每周換液２-３次。;生長特性：貼壁生長;形態(tài)特性：上皮細胞樣;相關產(chǎn)品有：Mouse Colon 38細胞、WB F344細胞、KE37細胞

Hs-746T Cells;背景說明：詳見相關文獻介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關產(chǎn)品有：NOZAWA細胞、CCRF/CEM-C7細胞、EAhy926細胞

NCIH2030 Cells;背景說明：詳見相關文獻介紹;傳代方法：１：３-１：４傳代；每周換液２-３次。;生長特性：貼壁生長;形態(tài)特性：上皮細胞樣;相關產(chǎn)品有：DoHH-2細胞、RH-30細胞、GP2-293細胞

HSC-3 Cells;背景說明：詳見相關文獻介紹;傳代方法：１ x １０^５ cells/１０cm dish;生長特性：貼壁生長;形態(tài)特性：上皮細胞;相關產(chǎn)品有：NCIH2081細胞、Nb2細胞、HUCEC細胞

BC-3H-1 Cells;背景說明：詳見相關文獻介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關產(chǎn)品有：H766T細胞、BALB/3T3 (clone A31)細胞、MCA 205細胞

MN-60 Cells;背景說明：B細胞白血病；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：懸浮;形態(tài)特性：詳見產(chǎn)品說明書;相關產(chǎn)品有：Wien133細胞、H-838細胞、HCC1599細胞

MCF10A Cells;背景說明：乳腺；上皮細胞；自發(fā)永生；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關產(chǎn)品有：NCI-H647細胞、GP5d細胞、CV-1.K細胞

KP-N-RT-BM-1 Cells;背景說明：詳見相關文獻介紹;傳代方法：１：２傳代;生長特性：貼壁生長;形態(tài)特性：成神經(jīng)細胞;相關產(chǎn)品有：OCIAML3細胞、KAT5細胞、578T細胞

PLCPRF5 Cells;背景說明：該細胞系分泌乙肝病毒表面抗原（HBsAg）。 此細胞系原先被支原體污染，后用BM-cycline去除支原體;傳代方法：１：２傳代;生長特性：貼壁生長;形態(tài)特性：上皮樣;相關產(chǎn)品有：SCL-II細胞、QBC939細胞、L929(NCTC)細胞

MM96L Cells;背景說明：黑色素瘤；淋巴結轉移；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關產(chǎn)品有：SF-767細胞、DoHH2細胞、IEC18細胞

GM04678 Cells;背景說明：詳見相關文獻介紹;傳代方法：每周２-３次。;生長特性：懸浮生長;形態(tài)特性：淋巴母細胞;相關產(chǎn)品有：P388細胞、L cells (TK-)細胞、GCT細胞

LTEP-sm 1 Cells;背景說明：小細胞肺癌；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關產(chǎn)品有：Mono-Mac-6細胞、UPCI-SCC-090細胞、SNU-475細胞

Abcam HCT 116 YTHDF2 KO Cells(提供STR鑒定圖譜)

AG08593 Cells(提供STR鑒定圖譜)

BayGenomics ES cell line KST044 Cells(提供STR鑒定圖譜)

BayGenomics ES cell line XB720 Cells(提供STR鑒定圖譜)

BP26(R80) Cells(提供STR鑒定圖譜)

CO7 Cells(提供STR鑒定圖譜)

DA03801 Cells(提供STR鑒定圖譜)

DA05821 Cells(提供STR鑒定圖譜)

GM00083 Cells(提供STR鑒定圖譜)

HCT-FET Cells;背景說明：結腸癌;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關產(chǎn)品有：KYSE 50細胞、H3255細胞、HCT-8細胞

KPL1 Cells;背景說明：浸潤性導管癌；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關產(chǎn)品有：HS-940-T細胞、C2BBe1細胞、MV 3細胞

H2.35 Cells;背景說明：肝；SV４０轉化；雌性；BALB/c;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關產(chǎn)品有：LNT-229細胞、CCD1112Sk細胞、Karpas 299細胞

H9c2 Cells;背景說明：詳見相關文獻介紹;傳代方法：１：２傳代;生長特性：貼壁生長　;形態(tài)特性：詳見產(chǎn)品說明書;相關產(chǎn)品有：DU_145細胞、HOS(TE85)細胞、FOX-NY細胞

NCI-H2110 Cells;背景說明：詳見相關文獻介紹;傳代方法：１：３-１：６傳代，每周換液２-３次;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：上皮細胞;相關產(chǎn)品有：E6-1細胞、G-292 clone A141B1細胞、Fukuoka University-Malignant mixed Mullerian Tumor-1細胞

CHO-S Cells;背景說明：詳見相關文獻介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關產(chǎn)品有：OPM-2細胞、NTera2 cl.D1細胞、KMB17細胞

H-676B Cells;背景說明：詳見相關文獻介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關產(chǎn)品有：MHCCLM3細胞、MN-9D細胞、NT2-D1細胞

MD Anderson-Metastatic Breast-453 Cells;背景說明：該細胞系由CailleauR在１９７６年從一名４８歲的患有轉移性乳腺癌的白人女性的心包滲出液中分離建立的。該細胞表達FGF的受體。;傳代方法：１：２-１：４傳代；２-３天換液１次;生長特性：貼壁生長;形態(tài)特性：上皮樣；多角形;相關產(chǎn)品有：Gingival carcinoma Neck Metastasis細胞、Okayama University Medical School-23細胞、FHL124細胞

NCI-H460[H460]人大細胞肺癌細胞全年復蘇|已有STR圖譜

HS-729 Cells;背景說明：詳見相關文獻介紹;傳代方法：１：２傳代；每周換液２-３次。;生長特性：貼壁生長;形態(tài)特性：成纖維細胞;相關產(chǎn)品有：Murine Long bone Osteocyte-Y4細胞、SKNMC細胞、RPMI 6666細胞

HConEpic Cells;背景說明：結膜；上皮 Cells;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關產(chǎn)品有：Vero 76 clone E-6細胞、KP-N-RT細胞、NCIH929細胞

OE-19 Cells;背景說明：詳見相關文獻介紹;傳代方法：１：２傳代;生長特性：貼壁生長;形態(tài)特性：上皮樣;相關產(chǎn)品有：Nthy-ori 3.1細胞、CTLA4Ig-24細胞、JM-1細胞

MS1 Cells;背景說明：MS１是１９９４年建株的胰島內皮細胞株。原代培養(yǎng)的胰島內皮細胞用抗G４１８的溫度敏感型SV４０大T抗原(tsA-５８-３)轉染?？剐钥寺∮每寺…h(huán)分離，并篩選吸收dil-Ac-LDL的。這株細胞保留了內皮細胞的許多特性，如吸收乙?；疞DL和表達八因子相關抗原及BEGF受體。;傳代方法：消化３-５分鐘。１：２。３天內可長滿。;生長特性：貼壁生長;形態(tài)特性：詳見產(chǎn)品說明書;相關產(chǎn)品有：H1522細胞、MS-751細胞、YES-2細胞

SW 579 Cells;背景說明：在裸鼠中成瘤(產(chǎn)生三級惡性紡錘狀巨細胞瘤)。 ;傳代方法：１：２傳代;生長特性：貼壁生長;形態(tài)特性：上皮細胞樣;相關產(chǎn)品有：ATN-1細胞、WM 115細胞、EPC細胞

32D.cl3 Cells;背景說明：骨髓淋巴瘤；C３H/HeJ;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：懸浮;形態(tài)特性：詳見產(chǎn)品說明書;相關產(chǎn)品有：Mouse Podocyte Clone-5細胞、LS-411N細胞、QBC939細胞

Hs68 Cells;背景說明：該細胞１９６９年由Owens RB建立。;傳代方法：１：２傳代;生長特性：貼壁生長　;形態(tài)特性：詳見產(chǎn)品說明書;相關產(chǎn)品有：DMS 114細胞、OCI-LY-1細胞、M21細胞

GSC#449 Cells(提供STR鑒定圖譜)

HAP1 PPP2R4 (-) 2 Cells(提供STR鑒定圖譜)

SUD4 Cells;背景說明：詳見相關文獻介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：懸浮;形態(tài)特性：淋巴母細胞;相關產(chǎn)品有：HNTEC細胞、T HEECs細胞、Hs688(A)T細胞

Metastatic Variant-522 Cells;背景說明：肺腺癌；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關產(chǎn)品有：NCI-H2291細胞、GH 3細胞、Granta 519細胞

MyLa2059 Cells;背景說明：皮膚；T淋巴細胞瘤;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：懸浮;形態(tài)特性：詳見產(chǎn)品說明書;相關產(chǎn)品有：SKMEL-24細胞、PC 61 5.3細胞、NCI-H1781細胞

MGHU1 Cells;背景說明：膀胱癌；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關產(chǎn)品有：WM2664細胞、MDA-MB-415細胞、RC-K8細胞

MDA.MB.231 Cells;背景說明：MDA-MB-２３１來自患有轉移乳腺腺癌的５１歲女病人的胸水。在裸鼠和ALS處理的BALB/c小鼠中，它能形成低分化腺癌（III級）。;傳代方法：消化３-５分鐘，１：２,３天內可長滿;生長特性：貼壁生長;形態(tài)特性：上皮樣;相關產(chǎn)品有：PANC 203細胞、VP267細胞、KY70細胞

SL-29 Cells;背景說明：胚成纖維細胞； White Leghorn SPAFAS;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關產(chǎn)品有：MB39細胞、LED-WiDr細胞、E0771細胞

SV-HUC Cells;背景說明：詳見相關文獻介紹;傳代方法：１：２傳代;生長特性：貼壁生長　;形態(tài)特性：詳見產(chǎn)品說明書;相關產(chǎn)品有：AD-293細胞、231-luc細胞、NCM356細胞

Sp2/O Cells;背景說明：該細胞是由綿羊紅細胞免疫的BALB/c小鼠脾細胞和P３X６３Ag８骨髓瘤細胞融合得到的。該細胞不分泌免疫球蛋白，對２０μg/ml的８-氮鳥嘌呤有抗性，對HAT比較敏感；該細胞可以作為細胞融合時的B細胞組分用于制備雜交瘤；鼠痘病毒陰性。;傳代方法：１：２傳代;生長特性：懸浮生長;形態(tài)特性：淋巴母細胞樣；圓形;相關產(chǎn)品有：X63-AG 8.653細胞、OUMS-23細胞、SCC4細胞

Hu02 Cells(提供STR鑒定圖譜)

KUN-DH-33 Cells(提供STR鑒定圖譜)

MRC-iPS-92 Cells(提供STR鑒定圖譜)

OCC-13 Cells(提供STR鑒定圖譜)

RLD-5 Cells(提供STR鑒定圖譜)

Ubigene A-549 MAPK11 KO Cells(提供STR鑒定圖譜)

UT-EC-2B Cells(提供STR鑒定圖譜)

HAP1 USP7 (-) Cells(提供STR鑒定圖譜)

OV1063 Cells;背景說明：卵巢上皮細胞癌;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關產(chǎn)品有：KYSE-30細胞、Colon38細胞、KMS-18細胞

HMy2.CIR Cells;背景說明：B細胞；EBV轉染；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：懸浮;形態(tài)特性：詳見產(chǎn)品說明書;相關產(chǎn)品有：P3X63 Ag8.653細胞、OCI/AML3細胞、MC-38細胞

MESSA Cells;背景說明：詳見相關文獻介紹;傳代方法：１：６-１：８傳代；每周２-３次。;生長特性：貼壁生長;形態(tài)特性：成纖維細胞樣　;相關產(chǎn)品有：M109細胞、KYSE-70細胞、L1210細胞

Hk-2 Cells;背景說明：該細胞屬源于正常腎的近曲小管細胞，通過導入HPV-１６ E６/E７基因而獲得永生化。將含有HPV-１６ E６/E７基因的重組的逆轉錄病毒載體pLXSN １６ E６/E７轉染外生包裝細胞Psi-２，Psi-２細胞產(chǎn)生的病毒再去感染兼嗜性包裝細胞系PA３１７，最后將PA３１７產(chǎn)生的病毒顆粒導入正常的腎皮質近曲小管細胞。盡管pLXSN １６ E６/E７中含有新霉素抗性，但未用G４１８篩選轉導克隆。Southern和FISH分析顯示HK-２細胞來源于單克隆。PCR檢測證實HK-２細胞基因組中含有E６/E７基因。;傳代方法：１：４傳代；２-３天換液１次;生長特性：貼壁生長;形態(tài)特性：上皮樣;相關產(chǎn)品有：B5537SKIN細胞、BT20細胞、PC-10細胞

NCI-1155 Cells;背景說明：詳見相關文獻介紹;傳代方法：每周換液２-３次。;生長特性：懸浮生長;形態(tài)特性：上皮細胞;相關產(chǎn)品有：GM05372細胞、MCF7-GFP細胞、102PT細胞

NCI-1155 Cells;背景說明：詳見相關文獻介紹;傳代方法：每周換液２-３次。;生長特性：懸浮生長;形態(tài)特性：上皮細胞;相關產(chǎn)品有：GM05372細胞、MCF7-GFP細胞、102PT細胞

QBI-293A Cells;背景說明：胚腎；腺病毒包裝;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關產(chǎn)品有：G401細胞、C33-A細胞、Hs729細胞

SUM52PE Cells;背景說明：乳腺癌；胸腔積液轉移；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關產(chǎn)品有：AtT-20細胞、451Lu細胞、JM1細胞

SW-1271 Cells;背景說明：詳見相關文獻介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關產(chǎn)品有：HeLa/S3細胞、HEK293T/17細胞、DLD 1細胞

SUDHL6 Cells;背景說明：詳見相關文獻介紹;傳代方法：１：３—１：６傳代，３—４天換液１次;生長特性：懸浮生長 ;形態(tài)特性：淋巴母細胞樣;相關產(chǎn)品有：H841細胞、RAOEC細胞、ATN-1細胞

NCIADR.RES Cells;背景說明：詳見相關文獻介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關產(chǎn)品有：SUNE 1細胞、SU-DHL-5細胞、3LL細胞

NCI-H125 Cells;背景說明：腺鱗狀肺癌；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關產(chǎn)品有：J82COT細胞、SKMEL28細胞、HT144-mel細胞

Molm14 Cells;背景說明：急性髓系白血??；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：懸浮;形態(tài)特性：詳見產(chǎn)品說明書;相關產(chǎn)品有：CAL78細胞、HCE-2 [50.B1]細胞、HS 445T細胞

MDA330 Cells;背景說明：詳見相關文獻介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關產(chǎn)品有：Pt K2細胞、PG [Human lung carcinoma]細胞、ROS-17/2.8細胞

SW-1783 Cells;背景說明：間變性星形細胞瘤；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關產(chǎn)品有：FRhK4細胞、CHOK1細胞、U14細胞

SW480/OXR Cells(提供STR鑒定圖譜)

HRMC Cells;背景說明：腎；系膜 Cells;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關產(chǎn)品有：Institute for Medical Research-90細胞、3T3-Swiss細胞、Hs852T細胞

MCF-7ADR Cells;背景說明：詳見相關文獻介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關產(chǎn)品有：Walker-Ca.256細胞、KASUMI1細胞、EJ 138細胞

CMT-93 Cells;背景說明：結腸癌；C５７BL/ICRF;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關產(chǎn)品有：Bac1 2F5細胞、D341MD細胞、H1105細胞

HNSC Cells;背景說明：神經(jīng)干 Cells;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關產(chǎn)品有：HCASMC細胞、MDAMB435S細胞、HEL細胞

PL12 Cells;背景說明：詳見相關文獻介紹;傳代方法：１：２傳代;生長特性：貼壁生長;形態(tài)特性：上皮樣;相關產(chǎn)品有：16HBE140細胞、PA-TU-8988S細胞、HIBEpiC細胞

WML2 Cells;背景說明：肺；成纖維 Cells;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關產(chǎn)品有：UMR-106細胞、BCP1細胞、K7M2細胞

CA 46 Cells;背景說明：該細胞源自Burkitt＇s淋巴瘤患者的B淋巴細胞，EBNA、Fc陰性。;傳代方法：１：２傳代;生長特性：懸浮生長;形態(tài)特性：淋巴母細胞樣;相關產(chǎn)品有：D283 Med細胞、WERI-Rb 1細胞、Colo741細胞

GM06141 Cells;背景說明：這株淋巴母細胞樣細胞株，源自一位３０歲白人男性一，患有惡性紅細胞白血病，能夠自然產(chǎn)生并能誘導球蛋白合成。細胞的EB病毒核抗原陰性，沒有表面免疫球蛋白與細胞質免疫球蛋白。HEL細胞表達HLA抗原(HLA-A３,AW３２,BW３５),β-２小球蛋白，一定比例的細胞還表達Ia抗原。這個細胞株提供了一種用于研究紅細胞分化和球蛋白基因表達的模型。它類似于小鼠中的血友病。;傳代方法：１：２傳代。３天內可長滿。;生長特性：懸浮生長;形態(tài)特性：淋巴母細胞樣;相關產(chǎn)品有：RBL-I細胞、THP 1細胞、NCI N87細胞

NCI-H460[H460]人大細胞肺癌細胞全年復蘇|已有STR圖譜

mIMCD-3 Cells;背景說明：腎；內髓集合管；上皮 Cells;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關產(chǎn)品有：NIH:OVCAR4細胞、BJA-B細胞、H1882細胞

HS5 Cells;背景說明：詳見相關文獻介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：上皮細胞樣;相關產(chǎn)品有：huH 1細胞、SK-MES-1細胞、Clone 929細胞

RPMI 8226/S Cells;背景說明：來源于一位６１歲的男性漿細胞瘤患者；可產(chǎn)生免疫球蛋白輕鏈，未檢測到重鏈。;傳代方法：按１：２傳代，５-６小時可以看到細胞分裂;生長特性：懸浮生長;形態(tài)特性：淋巴母細胞樣;相關產(chǎn)品有：AC16 [Human hybrid]細胞、SK-MEL28細胞、IPAM-WT細胞

CCFSTTG1 Cells;背景說明：詳見相關文獻介紹;傳代方法：１：３—１：６傳代；每周換液２-３次;生長特性：貼壁生長;形態(tài)特性：星形膠質細胞;相關產(chǎn)品有：CORL105細胞、SNT8細胞、Y3M細胞

HL-1 Cells;背景說明：心肌；SV４０轉化;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關產(chǎn)品有：RK-13細胞、BALB/c 3T3 clone A31細胞、SK-N-BE(2)細胞

KY-270 Cells;背景說明：詳見相關文獻介紹;傳代方法：１：５傳代;生長特性：貼壁生長;形態(tài)特性：上皮樣;相關產(chǎn)品有：SKLU-1細胞、D324細胞、NCIH1915細胞

BayGenomics ES cell line PST027 Cells(提供STR鑒定圖譜)

BayGenomics ES cell line XC739 Cells(提供STR鑒定圖譜)

CPTC-MAPK3-3 Cells(提供STR鑒定圖譜)

MC615 4C1 Cells(提供STR鑒定圖譜)

SC34.62 Cells(提供STR鑒定圖譜)

LM-MEL-69 Cells(提供STR鑒定圖譜)

" "PubMed=2041050; DOI=10.1093/jnci/83.11.757

Monks A., Scudiero D.A., Skehan P., Shoemaker R.H., Paull K.D., Vistica D.T., Hose C.D., Langley J., Cronise P., Vaigro-Wolff A., Gray-Goodrich M., Campbell H., Mayo J.G., Boyd M.R.

Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines.

J. Natl. Cancer Inst. 83:757-766(1991)

PubMed=1311061

Mitsudomi T., Steinberg S.M., Nau M.M., Carbone D.P., D'Amico D., Bodner S.M., Oie H.K., Linnoila R.I., Mulshine J.L., Minna J.D., Gazdar A.F.

p53 gene mutations in non-small-cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features.

Oncogene 7:171-180(1992)

PubMed=1563005

Giaccone G., Battey J., Gazdar A.F., Oie H.K., Draoui M., Moody T.W.

Neuromedin B is present in lung cancer cell lines.

Cancer Res. 52:2732s-2736s(1992)

PubMed=8385084; DOI=10.1111/j.1349-7006.1993.tb02851.x; PMCID=PMC5919128

Suzuki S., Takahashi T., Nakamura S., Koike K., Ariyoshi Y., Takahashi T., Ueda R.

Alterations of integrin expression in human lung cancer.

Jpn. J. Cancer Res. 84:168-174(1993)

PubMed=7718330; DOI=10.1016/0959-8049(94)00472-H

Baguley B.C., Marshall E.S., Whittaker J.R., Dotchin M.C., Nixon J., McCrystal M.R., Finlay G.J., Matthews J.H.L., Holdaway K.M., van Zijl P.L.

Resistance mechanisms determining the in vitro sensitivity to paclitaxel of tumour cells cultured from patients with ovarian cancer.

Eur. J. Cancer 31A:230-237(1995)

PubMed=8626706; DOI=10.1074/jbc.271.19.11477

Quinn K.A., Treston A.M., Unsworth E.J., Miller M.-J., Vos M., Grimley C., Battey J., Mulshine J.L., Cuttitta F.

Insulin-like growth factor expression in human cancer cell lines.

J. Biol. Chem. 271:11477-11483(1996)

PubMed=8806092; DOI=10.1002/jcb.240630505

Phelps R.M., Johnson B.E., Ihde D.C., Gazdar A.F., Carbone D.P., McClintock P.R., Linnoila R.I., Matthews M.J., Bunn P.A. Jr., Carney D.N., Minna J.D., Mulshine J.L.

NCI-Navy Medical Oncology Branch cell line data base.

J. Cell. Biochem. Suppl. 24:32-91(1996)

PubMed=10358721; DOI=10.18926/AMO/31626

Matsushita A., Tabata M., Ueoka H., Kiura K., Shibayama T., Aoe K., Kohara H., Harada M.

Establishment of a drug sensitivity panel using human lung cancer cell lines.

Acta Med. Okayama 53:67-75(1999)

PubMed=10700174; DOI=10.1038/73432

Ross D.T., Scherf U., Eisen M.B., Perou C.M., Rees C., Spellman P.T., Iyer V.R., Jeffrey S.S., van de Rijn M., Waltham M.C., Pergamenschikov A., Lee J.C.F., Lashkari D., Shalon D., Myers T.G., Weinstein J.N., Botstein D., Brown P.O.

Systematic variation in gene expression patterns in human cancer cell lines.

Nat. Genet. 24:227-235(2000)

PubMed=11030152; DOI=10.1038/sj.onc.1203815

Modi S., Kubo A., Oie H.K., Coxon A.B., Rehmatulla A., Kaye F.J.

Protein expression of the RB-related gene family and SV40 large T antigen in mesothelioma and lung cancer.

Oncogene 19:4632-4639(2000)

PubMed=11551417; DOI=10.1016/S0169-5002(01)00205-7

Yoon S.-S., Ahn K.-S., Kim S.-H., Shim Y.M., Kim J.

In vitro establishment of cis-diammine-dichloroplatinum(II) resistant lung cancer cell line and modulation of apoptotic gene expression as a mechanism of resistant phenotype.

Lung Cancer 33:221-228(2001)

PubMed=11583962; DOI=10.1016/S0002-9440(10)62521-7; PMCID=PMC1850523

Haruki N., Harano T., Masuda A., Kiyono T., Takahashi T., Tatematsu Y., Shimizu S., Mitsudomi T., Konishi H., Osada H., Fujii Y., Takahashi T.

Persistent increase in chromosome instability in lung cancer: possible indirect involvement of p53 inactivation.

Am. J. Pathol. 159:1345-1352(2001)

PubMed=12068308; DOI=10.1038/nature00766

Davies H.R., Bignell G.R., Cox C., Stephens P.J., Edkins S., Clegg S., Teague J.W., Woffendin H., Garnett M.J., Bottomley W., Davis N., Dicks E., Ewing R., Floyd Y., Gray K., Hall S., Hawes R., Hughes J., Kosmidou V., Menzies A., Mould C., Parker A., Stevens C., Watt S., Hooper S., Wilson R., Jayatilake H., Gusterson B.A., Cooper C.S., Shipley J.M., Hargrave D., Pritchard-Jones K., Maitland N.J., Chenevix-Trench G., Riggins G.J., Bigner D.D., Palmieri G., Cossu A., Flanagan A.M., Nicholson A., Ho J.W.C., Leung S.Y., Yuen S.T., Weber B.L., Seigler H.F., Darrow T.L., Paterson H.F., Marais R., Marshall C.J., Wooster R., Stratton M.R., Futreal P.A.

Mutations of the BRAF gene in human cancer.

Nature 417:949-954(2002)

PubMed=12794755; DOI=10.1002/ijc.11184

Endoh H., Yatabe Y., Shimizu S., Tajima K., Kuwano H., Takahashi T., Mitsudomi T.

RASSF1A gene inactivation in non-small cell lung cancer and its clinical implication.

Int. J. Cancer 106:45-51(2003)

PubMed=15746151; DOI=10.1093/hmg/ddi092

Izumi H., Inoue J., Yokoi S., Hosoda H., Shibata T., Sunamori M., Hirohashi S., Inazawa J., Imoto I.

Frequent silencing of DBC1 is by genetic or epigenetic mechanisms in non-small cell lung cancers.

Hum. Mol. Genet. 14:997-1007(2005)

PubMed=15748285; DOI=10.1186/1479-5876-3-11; PMCID=PMC555742

Adams S., Robbins F.-M., Chen D., Wagage D., Holbeck S.L., Morse H.C. 3rd, Stroncek D., Marincola F.M.

HLA class I and II genotype of the NCI-60 cell lines.

J. Transl. Med. 3:11.1-11.8(2005)

PubMed=15900046; DOI=10.1093/jnci/dji133

Mashima T., Oh-hara T., Sato S., Mochizuki M., Sugimoto Y., Yamazaki K., Hamada J.-i., Tada M., Moriuchi T., Ishikawa Y., Kato Y., Tomoda H., Yamori T., Tsuruo T.

p53-defective tumors with a functional apoptosome-mediated pathway: a new therapeutic target.

J. Natl. Cancer Inst. 97:765-777(2005)

PubMed=17088437; DOI=10.1158/1535-7163.MCT-06-0433; PMCID=PMC2705832

Ikediobi O.N., Davies H.R., Bignell G.R., Edkins S., Stevens C., O'Meara S., Santarius T., Avis T., Barthorpe S., Brackenbury L., Buck G., Butler A.P., Clements J., Cole J., Dicks E., Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J., Hunter C., Jenkinson A., Jones D., Kosmidou V., Lugg R., Menzies A., Miroo T., Parker A., Perry J., Raine K.M., Richardson D., Shepherd R., Small A., Smith R., Solomon H., Stephens P.J., Teague J.W., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., Reinhold W.C., Weinstein J.N., Stratton M.R., Futreal P.A., Wooster R.

Mutation analysis of 24 known cancer genes in the NCI-60 cell line set.

Mol. Cancer Ther. 5:2606-2612(2006)

PubMed=17332333; DOI=10.1158/0008-5472.CAN-06-3339

Okabe T., Okamoto I., Tamura K., Terashima M., Yoshida T., Satoh T., Takada M., Fukuoka M., Nakagawa K.

Differential constitutive activation of the epidermal growth factor receptor in non-small cell lung cancer cells bearing EGFR gene mutation and amplification.

Cancer Res. 67:2046-2053(2007)

PubMed=18083107; DOI=10.1016/j.cell.2007.11.025

Rikova K., Guo A.-L., Zeng Q.-F., Possemato A., Yu J., Haack H., Nardone J., Lee K., Reeves C., Li Y., Hu Y.-R., Tan Z.-P., Stokes M.P., Sullivan L., Mitchell J., Wetzel R., MacNeill J., Ren J.-M., Yuan J., Bakalarski C.E., Villen J., Kornhauser J.M., Smith B., Li D.-Q., Zhou X.-M., Gygi S.P., Gu T.-L., Polakiewicz R.D., Rush J., Comb M.J.

Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer.

Cell 131:1190-1203(2007)

PubMed=19372543; DOI=10.1158/1535-7163.MCT-08-0921; PMCID=PMC4020356

Lorenzi P.L., Reinhold W.C., Varma S., Hutchinson A.A., Pommier Y., Chanock S.J., Weinstein J.N.

DNA fingerprinting of the NCI-60 cell line panel.

Mol. Cancer Ther. 8:713-724(2009)

PubMed=19472407; DOI=10.1002/humu.21028; PMCID=PMC2900846

Blanco R., Iwakawa R., Tang M.-Y., Kohno T., Angulo B., Pio R., Montuenga L.M., Minna J.D., Yokota J., Sanchez-Cespedes M.

A gene-alteration profile of human lung cancer cell lines.

Hum. Mutat. 30:1199-1206(2009)

PubMed=19941903; DOI=10.1016/j.jviromet.2009.11.022

Karger A., Bettin B., Lenk M., Mettenleiter T.C.

Rapid characterisation of cell cultures by matrix-assisted laser desorption/ionisation mass spectrometric typing.

J. Virol. Methods 164:116-121(2010)

PubMed=20164919; DOI=10.1038/nature08768; PMCID=PMC3145113

Bignell G.R., Greenman C.D., Davies H.R., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.

Signatures of mutation and selection in the cancer genome.

Nature 463:893-898(2010)

PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458; PMCID=PMC2881662

Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.

A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

Cancer Res. 70:2158-2164(2010)

PubMed=20510196; DOI=10.1016/j.ijrobp.2009.12.076

Lee Y.S., Oh J.-H., Yoon S., Kwon M.-S., Song C.-W., Kim K.-H., Cho M.-J., Mollah M.L., Je Y.J., Kim Y.-D., Kim C.D., Lee J.-H.

Differential gene expression profiles of radioresistant non-small-cell lung cancer cell lines established by fractionated irradiation: tumor protein p53-inducible protein 3 confers sensitivity to ionizing radiation.

Int. J. Radiat. Oncol. Biol. Phys. 77:858-866(2010)

PubMed=20557307; DOI=10.1111/j.1349-7006.2010.01622.x; PMCID=PMC11158680

Iwakawa R., Kohno T., Enari M., Kiyono T., Yokota J.

Prevalence of human papillomavirus 16/18/33 infection and p53 mutation in lung adenocarcinoma.

Cancer Sci. 101:1891-1896(2010)

PubMed=22068913; DOI=10.1073/pnas.1111840108; PMCID=PMC3219108

Gillet J.-P., Calcagno A.M., Varma S., Marino M., Green L.J., Vora M.I., Patel C., Orina J.N., Eliseeva T.A., Singal V., Padmanabhan R., Davidson B., Ganapathi R., Sood A.K., Rueda B.R., Ambudkar S.V., Gottesman M.M.

Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance.

Proc. Natl. Acad. Sci. U.S.A. 108:18708-18713(2011)

PubMed=22336246; DOI=10.1016/j.bmc.2012.01.017

Kong D.-X., Yamori T.

JFCR39, a panel of 39 human cancer cell lines, and its application in the discovery and development of anticancer drugs.

Bioorg. Med. Chem. 20:1947-1951(2012)

PubMed=22347499; DOI=10.1371/journal.pone.0031628; PMCID=PMC3276511

Ruan X.-Y., Kocher J.-P.A., Pommier Y., Liu H.-F., Reinhold W.C.

Mass homozygotes accumulation in the NCI-60 cancer cell lines as compared to HapMap trios, and relation to fragile site location.

PLoS ONE 7:E31628-E31628(2012)

PubMed=22384151; DOI=10.1371/journal.pone.0032096; PMCID=PMC3285665

Lee J.-S., Kim Y.K., Kim H.J., Hajar S., Tan Y.L., Kang N.-Y., Ng S.H., Yoon C.N., Chang Y.-T.

Identification of cancer cell-line origins using fluorescence image-based phenomic screening.

PLoS ONE 7:E32096-E32096(2012)

PubMed=22460905; DOI=10.1038/nature11003; PMCID=PMC3320027

Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Nature 483:603-607(2012)

PubMed=22628656; DOI=10.1126/science.1218595; PMCID=PMC3526189

Jain M., Nilsson R., Sharma S., Madhusudhan N., Kitami T., Souza A.L., Kafri R., Kirschner M.W., Clish C.B., Mootha V.K.

Metabolite profiling identifies a key role for glycine in rapid cancer cell proliferation.

Science 336:1040-1044(2012)

PubMed=22961666; DOI=10.1158/2159-8290.CD-12-0112; PMCID=PMC3567922

Byers L.A., Wang J., Nilsson M.B., Fujimoto J., Saintigny P., Yordy J.S., Giri U., Peyton M., Fan Y.-H., Diao L.-X., Masrorpour F., Shen L., Liu W.-B., Duchemann B., Tumula P., Bhardwaj V., Welsh J., Weber S., Glisson B.S., Kalhor N., Wistuba I.I., Girard L., Lippman S.M., Mills G.B., Coombes K.R., Weinstein J.N., Minna J.D., Heymach J.V.

Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1.

Cancer Discov. 2:798-811(2012)

PubMed=23381221; DOI=10.3892/or.2013.2266; PMCID=PMC3621652

Suzuki M., Shiraishi K., Eguchi A., Ikeda K., Mori T., Yoshimoto K., Ohba Y., Yamada T., Ito T., Baba Y., Baba H.

Aberrant methylation of LINE-1, SLIT2, MAL and IGFBP7 in non-small cell lung cancer.

Oncol. Rep. 29:1308-1314(2013)

PubMed=23856246; DOI=10.1158/0008-5472.CAN-12-3342; PMCID=PMC4893961

Abaan O.D., Polley E.C., Davis S.R., Zhu Y.-L.J., Bilke S., Walker R.L., Pineda M.A., Gindin Y., Jiang Y., Reinhold W.C., Holbeck S.L., Simon R.M., Doroshow J.H., Pommier Y., Meltzer P.S.

The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology.

Cancer Res. 73:4372-4382(2013)

PubMed=23933261; DOI=10.1016/j.celrep.2013.07.018

Moghaddas Gholami A., Hahne H., Wu Z.-X., Auer F.J., Meng C., Wilhelm M., Kuster B.

Global proteome analysis of the NCI-60 cell line panel.

Cell Rep. 4:609-620(2013)

PubMed=24135919; DOI=10.1038/ncomms3617; PMCID=PMC4107456

Balbin O.A., Prensner J.R., Sahu A., Yocum A., Shankar S., Malik R., Fermin D., Dhanasekaran S.M., Chandler B., Thomas D., Beer D.G., Cao X.-H., Nesvizhskii A.I., Chinnaiyan A.M.

Reconstructing targetable pathways in lung cancer by integrating diverse omics data.

Nat. Commun. 4:2617.1-2617.13(2013)

PubMed=24279929; DOI=10.1186/2049-3002-1-20; PMCID=PMC4178206

Dolfi S.C., Chan L.L.-Y., Qiu J., Tedeschi P.M., Bertino J.R., Hirshfield K.M., Oltvai Z.N., Vazquez A.

The metabolic demands of cancer cells are coupled to their size and protein synthesis rates.

Cancer Metab. 1:20.1-20.13(2013)

PubMed=24465237; DOI=10.5808/GI.2013.11.4.245; PMCID=PMC3897853

Im C.-N., Kim B.M., Moon E.-Y., Hong D.-W., Park J.W., Hong S.H.

Characterization of H460R, a radioresistant human lung cancer cell line, and involvement of syntrophin beta 2 (SNTB2) in radioresistance.

Genomics Inform. 11:245-253(2013)

PubMed=24670534; DOI=10.1371/journal.pone.0092047; PMCID=PMC3966786

Varma S., Pommier Y., Sunshine M., Weinstein J.N., Reinhold W.C.

High resolution copy number variation data in the NCI-60 cancer cell lines from whole genome microarrays accessible through CellMiner.

PLoS ONE 9:E92047-E92047(2014)

PubMed=25120651; DOI=10.3892/ol.2014.2234; PMCID=PMC4114630

Suzuki M., Ikeda K., Shiraishi K., Eguchi A., Mori T., Yoshimoto K., Shibata H., Ito T., Baba Y., Baba H.

Aberrant methylation and silencing of IRF8 expression in non-small cell lung cancer.

Oncol. Lett. 8:1025-1030(2014)

PubMed=25485619; DOI=10.1038/nbt.3080

Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S., Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.-M.

A comprehensive transcriptional portrait of human cancer cell lines.

Nat. Biotechnol. 33:306-312(2015)

PubMed=25877200; DOI=10.1038/nature14397

Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M., Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S., Neve R.M.

A resource for cell line authentication, annotation and quality control.

Nature 520:307-311(2015)

PubMed=26589293; DOI=10.1186/s13073-015-0240-5; PMCID=PMC4653878

Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P., Loewer M., Sahin U., Castle J.C.

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Genome Med. 7:118.1-118.7(2015)

PubMed=27377824; DOI=10.1038/sdata.2016.52; PMCID=PMC4932877

Mestdagh P., Lefever S., Volders P.-J., Derveaux S., Hellemans J., Vandesompele J.

Long non-coding RNA expression profiling in the NCI60 cancer cell line panel using high-throughput RT-qPCR.

Sci. Data 3:160052-160052(2016)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017; PMCID=PMC4967469

Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Miroo T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

A landscape of pharmacogenomic interactions in cancer.

Cell 166:740-754(2016)

PubMed=27807467; DOI=10.1186/s13100-016-0078-4; PMCID=PMC5087121

Zampella J.G., Rodic N., Yang W.R., Huang C.R.L., Welch J., Gnanakkan V.P., Cornish T.C., Boeke J.D., Burns K.H.

A map of mobile DNA insertions in the NCI-60 human cancer cell panel.

Mob. DNA 7:20.1-20.11(2016)

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005; PMCID=PMC5501076

Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P., Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B., Liang H.

Characterization of human cancer cell lines by reverse-phase protein arrays.

Cancer Cell 31:225-239(2017)

PubMed=28408844; DOI=10.2147/OTT.S128416; PMCID=PMC5384690

Townsend M.H., Anderson M.D., Weagel E.G., Velazquez E.J., Weber K.S., Robison R.A., O'Neill K.L.

Non-small-cell lung cancer cell lines A549 and NCI-H460 express hypoxanthine guanine phosphoribosyltransferase on the plasma membrane.

Onco Targets Ther. 10:1921-1932(2017)

PubMed=29444439; DOI=10.1016/j.celrep.2018.01.051; PMCID=PMC6343826

Yuan T.L., Amzallag A., Bagni R., Yi M., Afghani S., Burgan W., Fer N., Strathern L.A., Powell K., Smith B., Waters A.M., Drubin D.A., Thomson T., Liao R., Greninger P., Stein G.T., Murchie E., Cortez E., Egan R.K., Procter L., Bess M., Cheng K.T., Lee C.-S., Lee L.C., Fellmann C., Stephens R., Luo J., Lowe S.W., Benes C.H., McCormick F.

Differential effector engagement by oncogenic KRAS.

Cell Rep. 22:1889-1902(2018)

PubMed=29681454; DOI=10.1016/j.cell.2018.03.028; PMCID=PMC5935540

McMillan E.A., Ryu M.-J., Diep C.H., Mendiratta S., Clemenceau J.R., Vaden R.M., Kim J.-H., Motoyaji T., Covington K.R., Peyton M., Huffman K., Wu X.-F., Girard L., Sung Y., Chen P.-H., Mallipeddi P.L., Lee J.Y., Hanson J., Voruganti S., Yu Y., Park S., Sudderth J., DeSevo C., Muzny D.M., Doddapaneni H., Gazdar A.F., Gibbs R.A., Hwang T.H., Heymach J.V., Wistuba I.I., Coombes K.R., Williams N.S., Wheeler D.A., MacMillan J.B., DeBerardinis R.J., Roth M.G., Posner B.A., Minna J.D., Kim H.S., White M.A.

Chemistry-first approach for nomination of personalized treatment in lung cancer.

Cell 173:864-878.e29(2018)

PubMed=30038707; DOI=10.18632/oncotarget.25642; PMCID=PMC6049873

Du L.-Q., Zhao Z.-Z., Suraokar M.B., Shelton S.S., Ma X.-Y., Hsiao T.-H., Minna J.D., Wistuba I.I., Pertsemlidis A.

LMO1 functions as an oncogene by regulating TTK expression and correlates with neuroendocrine differentiation of lung cancer.

Oncotarget 9:29601-29618(2018)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747; PMCID=PMC6445675

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Cancer Res. 79:1263-1273(2019)

PubMed=31068700; DOI=10.1038/s41586-019-1186-3; PMCID=PMC6697103

Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. 3rd, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Nature 569:503-508(2019)

PubMed=31803961; DOI=10.1002/jcb.29564; PMCID=PMC7496084

Mulshine J.L., Ujhazy P., Antman M., Burgess C.M., Kuzmin I.A., Bunn P.A. Jr., Johnson B.E., Roth J.A., Pass H.I., Ross S.M., Aldige C.R., Wistuba I.I., Minna J.D.

From clinical specimens to human cancer preclinical models -- a journey the NCI-cell line database-25 years later.

J. Cell. Biochem. 121:3986-3999(2020)"